Bristol Myers Squibb today announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic ...

Alecensa (alectinib) demonstrated a 22% reduction in the risk of death compared with Xalkori (crizotinib) in the frontline ...

Medical research involves research in a wide range of fields, such as biology, chemistry, pharmacology and toxicology with the goal of developing new medicines or medical procedures or improving the ...

Roswell Park experts discuss their approach to whole-person survivorship care and strategies for tailoring comprehensive care plans to an individual’s need. Many Paths, One Purpose: After the Bell: ...

Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.